MedTrace Logo

Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4

NCT01900704 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 810

Last updated 2020-11-09

Study results available
· View outcomes & findings →

Summary

To investigate the efficacy and safety of SER120 nasal spray formulations in patients with nocturia

Conditions

  • Nocturia

Interventions

DRUG

SER120 750 ng

SER120 750 ng

DRUG

SER120 1500 ng

SER120 1500 ng

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Serenity Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01900704 on ClinicalTrials.gov